Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Senaparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 19/20 | 0.56 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 14/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.54 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Senaparib SCHEMBL29371993 | 1.00 | PARP1 (0.56) | PARP1PARP2MAP4K4CLK2MAP4K2 | |
| Senaparib SCHEMBL12822522 | 1.00 | PARP1 (0.56) | PARP1PARP2MAP4K4CLK2MAP4K2 | |
| Senaparib SCHEMBL15420063 | 0.99 | PARP1 (0.55) | PARP1PARP2MAP4K4CLK2MAP4K2 | |
| Senaparib SCHEMBL26929517 | 0.99 | PARP1 (0.55) | PARP1PARP2MAP4K4CLK2MAP4K2 | |
| Senaparib SCHEMBL30543533 | 0.99 | PARP1 (0.55) | PARP1PARP2MAP4K4CLK2MAP4K2 | |
| SCHEMBL12822378 | 0.93 | PARP1 (0.48) | PARP1PARP2MAP4K4CLK2MAP4K2 | |
| SCHEMBL22738203 | 0.93 | PARP1 (0.48) | PARP1PARP2MAP4K4CLK2MAP4K2 | |
| SCHEMBL29722423 | 0.93 | PARP1 (0.48) | PARP1PARP2MAP4K4CLK2MAP4K2 | |
| SCHEMBL24440246 | 0.93 | PARP1 (0.54) | PARP1PARP2MAP4K4CLK2MAP4K2 | |
| SCHEMBL12822033 | 0.93 | PARP1 (0.56) | PARP1PARP2MAP4K4CLK2MAP4K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-12544378-B2 | Solid pharmaceutical formulation of PARP inhibitors and use thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2026-02-10 | — | — | US | claimed |
| US-12534454-B2 | Crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and preparation thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2026-01-27 | — | — | US | claimed |
| US-20240082166-A1 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-14 | — | — | US | claimed |
| US-20230263801-A1 | COMBINATION THERAPY OF PARP INHIBITORS | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-24 | — | — | US | claimed |
| EP-3278803-B1 | SOLID PHARMACEUTICAL DOSAGE FORM OF PARP INHIBITOR, AND APPLICATION OF SOLID PHARMACEUTICAL DOSAGE FORM OF PARP INHIBITOR | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2022-06-22 | — | — | EP | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | disclosed |
| US-12534454-B2 | Crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and preparation thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2026-01-27 | — | — | US | disclosed |
| US-12534454-B2 | Crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and preparation thereof | Impact Therapeutics (Shanghai), Inc (CN) | 2026-01-27 | — | — | US | disclosed |
| WO-2025061057-A1 | USE OF A PARP INHIBITOR IN MAINTENANCE THERAPY OF OVARIAN CANCER | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025056690-A1 | PARP1- AND IMMUNE-CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER PATIENTS OVEREXPRESSING UBQLN1 AND/OR UBQLN4 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-03-20 | — | — | WO | disclosed |
| US-20230399316-A1 | CRYSTAL FORMS OF 5-FLUORO-1-(4-FLUORO-3-(4-(PYRIMIDIN-2-YL)PIPERAZINE-1-CARBONYL)BENZYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND PREPARATION THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399316-A1 | CRYSTAL FORMS OF 5-FLUORO-1-(4-FLUORO-3-(4-(PYRIMIDIN-2-YL)PIPERAZINE-1-CARBONYL)BENZYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND PREPARATION THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230263801-A1 | COMBINATION THERAPY OF PARP INHIBITORS | Impact Therapeutics (Shanghai), Inc (CN) | 2023-08-24 | — | — | US | disclosed |
| EP-3278803-B1 | SOLID PHARMACEUTICAL DOSAGE FORM OF PARP INHIBITOR, AND APPLICATION OF SOLID PHARMACEUTICAL DOSAGE FORM OF PARP INHIBITOR | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2022-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082166-A1 | ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF | PARP1, PARP15, PARP11 | PARP1 1/4885PARP2 4/4885MAP4K4 3243/4885 |
| US-20230263801-A1 | COMBINATION THERAPY OF PARP INHIBITORS | PARP2, PARP1, PARP3 | PARP1 2/4885PARP2 1/4885MAP4K4 1559/4885 |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | PARP1, PARP15, PARP11 | PARP1 1/4885PARP2 4/4885MAP4K4 1587/4885 |
| US-12544378-B2 | Solid pharmaceutical formulation of PARP inhibitors and use thereof | PARP1, PARP2, PARP15 | PARP1 1/4885PARP2 2/4885MAP4K4 2019/4885 |
| US-12534454-B2 | Crystal forms of 5-fluoro-1-(4-fluoro-3-(4-(pyrimidin-2-yl)piperazine-1-carbonyl)benzyl)quinazoline-2,4(1H,3H)-dione and preparation thereof | FLNA, CYP4F8, F8 | PARP1 181/4885PARP2 214/4885MAP4K4 1691/4885 |
| US-20230399316-A1 | CRYSTAL FORMS OF 5-FLUORO-1-(4-FLUORO-3-(4-(PYRIMIDIN-2-YL)PIPERAZINE-1-CARBONYL)BENZYL)QUINAZOLINE-2,4(1H,3H)-DIONE AND PREPARATION THEREOF | NT5C, DCUN1D5, PYM1 | PARP1 133/4885PARP2 312/4885MAP4K4 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.